{"ctNumber":"2023-506440-16-00","ctStatus":"Authorised","decisionDate":"2024-02-20T16:27:52.082","publishDate":"2025-12-11T02:47:23.895072339","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":108754,"rowSubjectCount":0,"products":[{"id":450764,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00082MIG","euMpNumber":"SCP15687495","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"ABIRATERONE ACETATE","euSubstNumber":"SUB31647","productSubstances":[{"substancePk":"430598","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"ABIRATERONE ACETATE","substanceEvCode":"SUB31647","synonyms":[]}],"atcCode":"H02AB06","atcName":"PREDNISOLONE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"glucocorticoid","sponsorProductCodeEdit":"Prednisolone","miaNumber":"1573 IMP","scientificProductEvCode":"SCP15687495","scientificProductPharmEvCode":"PHF00082MIG","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"PREDNISOLONE","jsonActiveSubstanceNames":"abiraterone acetate","pharmaceuticalFormDisplay":"PHF00082MIG"},{"id":450766,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00243MIG","euMpNumber":"SCP65085035","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"LIDOCAINE HYDROCHLORIDE MONOHYDRATE, METHYLPREDNISOLONE ACETATE","euSubstNumber":"SUB02922MIG, SUB03255MIG","productSubstances":[{"substancePk":"431385","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"LIDOCAINE HYDROCHLORIDE MONOHYDRATE","substanceEvCode":"SUB02922MIG","synonyms":[]},{"substancePk":"423458","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"METHYLPREDNISOLONE ACETATE","substanceEvCode":"SUB03255MIG","synonyms":[]}],"atcCode":"H02AB04","atcName":"METHYLPREDNISOLONE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"Glucocorticoids","sponsorProductCodeEdit":"Methylprednisolone","miaNumber":"1573 IMP","scientificProductEvCode":"SCP65085035","scientificProductPharmEvCode":"PHF00243MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS BOLUS USE"],"allSubstancesChemicals":true,"productName":"METHYLPREDNISOLONE","jsonActiveSubstanceNames":"lidocaine hydrochloride monohydrate, methylprednisolone acetate","pharmaceuticalFormDisplay":"PHF00243MIG"},{"id":450765,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9865104","productPharmForm":"ORAL SOLUTION","euMpNumber":"PRD3342092","marketingAuthNumber":"EU/1/01/171/001","prodAuthStatus":2,"prodName":"Rapamune 1 mg/mL oral solution","pharmForm":"ORAL SOLUTION","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/000273","nameOrg":"PFIZER EUROPE MA EEIG","productSubstances":[{"productPk":"9865104","substancePk":"233258","nameOrg":"PFIZER EUROPE MA EEIG","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG","synonyms":["SEL-110.36","RAPAMYCIN","NPG-12G","(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone"]}],"atcCode":"L04AA10","atcName":"SIROLIMUS","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"immunosuppressant","evCode":"PRD3342092","sponsorProductCodeEdit":"Sirolimus","miaNumber":"1573 IMP","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"Rapamune 1 mg/mL oral solution","jsonActiveSubstanceNames":"sirolimus","pharmaceuticalFormDisplay":"ORAL SOLUTION"},{"id":450767,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10196403","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD10196403","prodAuthStatus":1,"prodName":"rAAV8-hSGCG","pharmForm":"SOLUTION FOR INFUSION","sponsorProductCode":"ATA-200","activeSubstanceName":"ADENO-ASSOCIATED VIRUS SEROTYPE 8 EXPRESSING THE HUMAN GAMMA-SARCOGLYCAN GENE","euSubstNumber":"SUB254592","nameOrg":"ATAMYO THERAPEUTICS","productSubstances":[{"productPk":"10196403","substancePk":"258374","nameOrg":"ATAMYO THERAPEUTICS","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"ADENO-ASSOCIATED VIRUS SEROTYPE 8 EXPRESSING THE HUMAN GAMMA-SARCOGLYCAN GENE","substanceEvCode":"SUB254592","synonyms":["ATA-200","Adeno-associated virus serotype 8 containing the SGCG gene"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EMA/OD/0000078678","otherMedicinalProduct":"GTMP: genetically modified recombinant viral: vector serotype 8 of the adeno-associated virus (AAV)","evCode":"PRD10196403","sponsorProductCodeEdit":"ATA-200","therapies":[{"id":5639,"advancedTherapyType":"3","geneOfInterest":"human Sarcoglycan Gamma","description":"ATA-200 is a genetically modified recombinant (r) viral vector composed of the viral capsid of the serotype 8 of the adeno-associated virus (AAV) and the complementary DNA (cDNA) sequence (hSGCG) encoding for the human gamma-sarcoglycan under the transcriptional control of the human muscle creatine kinase promoter (tMCK)","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"rAAV8-hSGCG","jsonActiveSubstanceNames":"adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"A Phase I/II, open-label, dose escalation study to evaluate the safety of 2 doses of intravenous ATA-200, an adeno-associated viral vector carrying the human gamma-sarcoglycan gene, in patients with gamma-sarcoglycanopathy (limb-girdle muscular dystrophy LGMDR5, formerly LGMD2C).","fullTitleTranslations":[{"id":8781362,"uuid":"443f3dca-09a0-415b-9a3b-16a2d35064b3","attributeTranslation":"Etude ouverte de Phase 1-2, à doses croissantes, pour évaluer l'innocuité de 2 doses par voie intraveineuse d'ATA-200, un vecteur viral adéno-associé portant le gène humain de la gamma-sarcoglycane, chez des patients atteints de gamma-sarcoglycanopathie (LGMDR5, anciennement LGMD2C).","language":34,"languageDescription":"French (France)"}],"publicTitle":"ATA-200 gene therapy trial in patients with LGMDR5","publicTitleTranslations":[{"id":8781371,"uuid":"f89984e2-aac4-427c-9763-e3bcd99ff72a","attributeTranslation":"Essai de thérapie génique ATA-200 chez des patients atteints de LGMDR5","language":34,"languageDescription":"French (France)"},{"id":8781370,"uuid":"f89984e2-aac4-427c-9763-e3bcd99ff72a","attributeTranslation":"Studio di terapia genica ATA-200 in pazienti affetti da LGMDR5","language":14,"languageDescription":"Italian"}],"shortTitle":"ATA-003-GSAR","secondaryIdentifyingNumbers":{"nctNumber":{"id":461386,"number":"NCT05973630"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"7","trialCategory":"2","justificationForTrialCategory":"Phase 1-2: safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy","trialCategoryId":99113},"medicalCondition":{"partIMedicalConditions":[{"id":112654,"medicalCondition":"limb-girdle muscular dystrophy type R5 (previously named LGMD2C)","medicalConditionTranslations":[{"id":8781322,"uuid":"83cad983-a339-4cd2-9fd0-49d0073e8f06","attributeTranslation":"Dystrophie musculaire des ceintures liée au gamma-sarcoglycane R5","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":100000012561,"version":"20.0","level":"PT","termName":"Muscular dystrophy","classificationCode":"10028356","organClass":100000004850,"active":false}]},"trialObjective":{"trialScopes":[{"code":"4","trialScopeId":327927}],"mainObjective":"to assess the safety and tolerability of intravenous administration ATA-200 in pediatric ambulant patients with LGMDR5 at two different dosage levels and to select the recommended dose for future studies.","mainObjectiveTranslations":[{"id":8781369,"uuid":"a7274ae8-7326-48e6-94cf-931d1c998eba","attributeTranslation":"Évaluer l'innocuité et la tolérabilité de l'administration intraveineuse d'ATA-200 chez des patients pédiatriques ambulatoires atteints de LGMDR5 à deux niveaux de dosage différents et sélectionner la dose recommandée pour les études futures","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":377818,"number":1,"secondaryObjective":"To collect preliminary efficacy data","secondaryObjectiveTranslations":[{"id":8781372,"uuid":"98d377ef-991b-43a4-83a2-96065d9667fd","attributeTranslation":"Collecter des données préliminaires d’efficacité","language":34,"languageDescription":"French (France)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":725486,"number":1,"principalInclusionCriteria":"Ambulant male or female patients at least 6 and less than 12 years of age at screening","principalInclusionCriteriaTranslations":[{"id":8781363,"uuid":"f24682ba-a8e5-4aa6-a2a9-171d2012043b","attributeTranslation":"Patients ambulants de sexe masculin ou féminin âgés d'au moins 6 ans et de moins de 12 ans au moment du dépistage","language":34,"languageDescription":"French (France)"}]},{"id":725487,"number":2,"principalInclusionCriteria":"Confirmed LGMDR5 diagnosis before age of 10, based on clinical presentation and genotyping identifying the SGCG gene mutations","principalInclusionCriteriaTranslations":[{"id":8781364,"uuid":"3627f93e-1519-4961-a445-a81738f5c38e","attributeTranslation":"Diagnostic LGMDR5 confirmé avant l'âge de 10 ans, basé sur la présentation clinique et le génotypage identifiant les mutations du gène SGCG","language":34,"languageDescription":"French (France)"}]},{"id":725488,"number":3,"principalInclusionCriteria":"Able to Perform the 10-meter walk test (10MWT) within 15 sec without help, such as cane, or bilateral help, such as elbow crutches or orthotic devices below the knees and to rise from a standard-height chair with or without arm support","principalInclusionCriteriaTranslations":[{"id":8781365,"uuid":"252b7005-50bb-4267-b1ef-ed13b37d4e3b","attributeTranslation":"Capable de :\n• Effectuer le test de marche de 10 mètres (10 MWT) en 15 secondes sans aide, comme une canne, ou une aide bilatérale, comme des béquilles ou des orthèses sous les genoux\n• Se lever d'une chaise de hauteur standard avec ou sans accoudoir","language":34,"languageDescription":"French (France)"}]},{"id":725489,"number":4,"principalInclusionCriteria":"Signed written informed consent before any study related procedure is performed","principalInclusionCriteriaTranslations":[{"id":8781366,"uuid":"e23c3c9c-c123-4719-a222-fc7777304cef","attributeTranslation":"Consentement éclairé écrit signé avant toute procédure liée à l'étude est effectuée","language":34,"languageDescription":"French (France)"}]},{"id":725490,"number":5,"principalInclusionCriteria":"Patient medical status sufficiently stable and ability of patient and parents/legal guardian, in the opinion of the investigator, to adhere to the study visits schedule and other protocol requirements.","principalInclusionCriteriaTranslations":[{"id":8781367,"uuid":"1a827eb6-9ab8-4326-8e53-342d693fdd59","attributeTranslation":"Statut médical du patient suffisamment stable et capacité du patient et des parents/tuteur légal, de l'avis de l'investigateur, à respecter le calendrier des visites d'étude et les autres exigences du protocole.","language":34,"languageDescription":"French (France)"}]},{"id":725491,"number":6,"principalInclusionCriteria":"Seronegative patients for neutralizing antibodies against AAV8","principalInclusionCriteriaTranslations":[{"id":8781368,"uuid":"47743d4b-c0c6-40f8-a900-dbc9c53903e4","attributeTranslation":"Patients séronégatifs pour les anticorps neutralisant AAV8","language":34,"languageDescription":"French (France)"}]}],"principalExclusionCriteria":[{"id":1244645,"number":1,"principalExclusionCriteria":"Previous participation in gene and cell therapy trials","principalExclusionCriteriaTranslations":[{"id":8781348,"uuid":"d9461e61-42d0-4378-8b9a-d9238e8c3b83","attributeTranslation":"Participation antérieure à des essais de thérapie génique et cellulaire","language":34,"languageDescription":"French (France)"}]},{"id":1244646,"number":10,"principalExclusionCriteria":"Inability to cooperate with muscle testing or to perform respiratory function tests","principalExclusionCriteriaTranslations":[{"id":8781349,"uuid":"b8caff7c-19c4-4f99-b682-ea6b856c062e","attributeTranslation":"Incapacité à coopérer avec les tests musculaires ou à effectuer des tests de la fonction respiratoire","language":34,"languageDescription":"French (France)"}]},{"id":1244647,"number":11,"principalExclusionCriteria":"Presence or history of concomitant muscular or other medical condition that might interfere with LGMDR5 evolution or that would confound scientific rigor or interpretation of results, e.g., current infectious episode (pulmonary, ENT, etc.), abnormal laboratory test if clinically significant","principalExclusionCriteriaTranslations":[{"id":8781350,"uuid":"aac0c3b0-4e4a-4456-93d5-ec320ecbae5d","attributeTranslation":"Présence ou antécédents de troubles musculaires ou médicaux concomitants qui pourraient interférer avec l'évolution du LGMDR5 ou qui confondraient la rigueur scientifique ou l'interprétation des résultats, par exemple, épisode infectieux actuel (pulmonaire, ORL, etc.), test de laboratoire anormal si cliniquement significatif","language":34,"languageDescription":"French (France)"}]},{"id":1244648,"number":12,"principalExclusionCriteria":"Current or history of significant heart, lung, hepato-biliary or renal disease or impairment that jeopardize the safety of the subject according to the investigator","principalExclusionCriteriaTranslations":[{"id":8781351,"uuid":"4ee6924f-c650-41a5-a844-7be75d2d22aa","attributeTranslation":"Courant ou antécédents de maladie ou d'insuffisance cardiaque, pulmonaire, hépato-biliaire ou rénale significative qui compromet la sécurité du sujet selon l'investigateur","language":34,"languageDescription":"French (France)"}]},{"id":1244649,"number":13,"principalExclusionCriteria":"Acute illness within 4 weeks of the anticipated IMP administration which may interfere with study assessments","principalExclusionCriteriaTranslations":[{"id":8781352,"uuid":"779c9766-fabc-457d-93d1-33cfb322408e","attributeTranslation":"Maladie aiguë dans les 4 semaines suivant l'administration prévue de l'IMP, ce qui peut interférer avec les évaluations de l'étude","language":34,"languageDescription":"French (France)"}]},{"id":1244650,"number":14,"principalExclusionCriteria":"Current participation in a clinical trial of another investigational medicinal product","principalExclusionCriteriaTranslations":[{"id":8781353,"uuid":"b6a699ed-ee41-4540-bd7f-3a6d533a451e","attributeTranslation":"Participation actuelle à un essai clinique d'un autre médicament expérimental","language":34,"languageDescription":"French (France)"}]},{"id":1244651,"number":2,"principalExclusionCriteria":"Any condition that would contraindicate treatment with immunosuppressant therapy","principalExclusionCriteriaTranslations":[{"id":8781354,"uuid":"702196ae-3542-405b-a0ad-38d4e76a1cd0","attributeTranslation":"Toute condition qui contre-indiquerait un traitement immunosuppresseur","language":34,"languageDescription":"French (France)"}]},{"id":1244652,"number":3,"principalExclusionCriteria":"Presence of any permanent items (e.g., metal braces) precluding undergoing MRI","principalExclusionCriteriaTranslations":[{"id":8781355,"uuid":"e48b6d07-a226-47ad-a639-f934d55c593c","attributeTranslation":"Présence d'éléments permanents (par exemple, des accolades métalliques) empêchant de subir une IRM","language":34,"languageDescription":"French (France)"}]},{"id":1244653,"number":4,"principalExclusionCriteria":"Any vaccination 1 month prior to the planned IMP administration","principalExclusionCriteriaTranslations":[{"id":8781356,"uuid":"b2dc1460-6df0-4782-9c8f-1e4b1e54da60","attributeTranslation":"Toute vaccination 1 mois avant l'administration prévue de l'IMP","language":34,"languageDescription":"French (France)"}]},{"id":1244654,"number":5,"principalExclusionCriteria":"Serology consistent with HIV exposure or active hepatitis B or C infection","principalExclusionCriteriaTranslations":[{"id":8781357,"uuid":"9907ca4b-18f0-4cc3-b7a1-24fbb7c68b0f","attributeTranslation":"Sérologie compatible avec une exposition au VIH ou une infection active à l'hépatite B ou C","language":34,"languageDescription":"French (France)"}]},{"id":1244655,"number":6,"principalExclusionCriteria":"Grade 2 or higher lab abnormalities for LFT (except isolated AST increase), bilirubin, creatinine, hemoglobin, WBC count, platelet count, PT, and a PTT, according to current version of CTCAE. Isolated AST increase associated with CK levels > 800 U/L, ALT < 2 x ULN, and GLDH within normal range, is not exclusionary.","principalExclusionCriteriaTranslations":[{"id":8781358,"uuid":"dc6d9549-76fe-4773-847c-190a1684040a","attributeTranslation":"Anomalies de laboratoire de grade 2 ou supérieur pour le LFT (sauf augmentation isolée de l'AST), la bilirubine, la créatinine, l'hémoglobine, le nombre de globules blancs, le nombre de plaquettes, le PT et un PTT, selon la version actuelle du CTCAE. L'augmentation isolée de l'AST associée à des taux de CK > 800 U/L, d'ALT < 2 x LSN et de GLDH dans la plage normale n'est pas exclusive.","language":34,"languageDescription":"French (France)"}]},{"id":1244656,"number":7,"principalExclusionCriteria":"Known hypersensitivity to IMP excipients, to eculizumab, murine proteins, or any excipients in eculizumab formulation, and to contrast media","principalExclusionCriteriaTranslations":[{"id":8781359,"uuid":"48baf019-47e6-457a-9b34-c708d7d11f3e","attributeTranslation":"Hypersensibilité connue aux excipients de l'IMP, à l'éculizumab, aux protéines murines ou à tout excipient de la formulation de l'éculizumab et aux produits de contraste","language":34,"languageDescription":"French (France)"}]},{"id":1244657,"number":8,"principalExclusionCriteria":"Cardiomyopathy based on physical and cardiological examination and echocardiography with Left Ventricular Ejection Fraction (LVEF) below 50%","principalExclusionCriteriaTranslations":[{"id":8781360,"uuid":"05387ec0-6e8a-45b0-b990-a1603b8c4fa0","attributeTranslation":"Cardiomyopathie basée sur un examen physique et cardiologique et une échocardiographie avec une fraction d'éjection ventriculaire gauche (FEVG) inférieure à 50%","language":34,"languageDescription":"French (France)"}]},{"id":1244658,"number":9,"principalExclusionCriteria":"Any respiratory assistance, including non-invasive daytime or nocturnal ventilation","principalExclusionCriteriaTranslations":[{"id":8781361,"uuid":"af547c46-c51c-46dd-b515-a263a44e2e6d","attributeTranslation":"Toute assistance respiratoire, y compris la ventilation diurne ou nocturne non invasive","language":34,"languageDescription":"French (France)"}]}]},"endPoint":{"primaryEndPoints":[{"id":848993,"number":1,"endPoint":"incidence of AEs recording throughout the study","isPrimary":true,"endPointTranslations":[{"id":8781323,"uuid":"cf698d28-0b40-4798-8bec-811b011422ba","attributeTranslation":"incidence des événements indésirables enregistrés tout au long de l'étude","language":34,"languageDescription":"French (France)"}]},{"id":848994,"number":2,"endPoint":"incidence of clinically relevant abnormalities detection in vital signs","isPrimary":true,"endPointTranslations":[{"id":8781324,"uuid":"cca65d7a-2e77-4449-9b7a-9fd5c7644826","attributeTranslation":"incidence des anomalies cliniquement pertinentes des signes vitaux","language":34,"languageDescription":"French (France)"}]},{"id":848995,"number":3,"endPoint":"physical examination findings","isPrimary":true,"endPointTranslations":[{"id":8781325,"uuid":"97612016-2d6b-4628-a9dc-80db5526627f","attributeTranslation":"Résultats d'examens physiques complets","language":34,"languageDescription":"French (France)"}]},{"id":848996,"number":4,"endPoint":"vital signs","isPrimary":true,"endPointTranslations":[{"id":8781326,"uuid":"52d2c13e-99a3-4a81-83ba-b50a5015da21","attributeTranslation":"les signes vitaux","language":34,"languageDescription":"French (France)"}]},{"id":848997,"number":5,"endPoint":"myalgia assessment","isPrimary":true,"endPointTranslations":[{"id":8781327,"uuid":"615b97c8-9ca7-41df-bba1-80f2af72dcde","attributeTranslation":"l'évaluation de la myalgie","language":34,"languageDescription":"French (France)"}]},{"id":848998,"number":6,"endPoint":"cardiac assessment","isPrimary":true,"endPointTranslations":[{"id":8781328,"uuid":"5b068611-bdc0-464f-8ae7-57e7eaada025","attributeTranslation":"évaluations cardiaques","language":34,"languageDescription":"French (France)"}]},{"id":848999,"number":7,"endPoint":"laboratory determinations","isPrimary":true,"endPointTranslations":[{"id":8781329,"uuid":"c816c390-9942-47ee-9357-060f63aab4ab","attributeTranslation":"déterminations de laboratoire","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":849000,"number":1,"endPoint":"Efficacy: muscle Function Tests: North Star Assessment for Neuromuscular Disorders (NSAD) and Performance of the Upper Limb (PUL)","isPrimary":false,"endPointTranslations":[{"id":8781330,"uuid":"f8e966c5-2409-49f4-9365-fd004d9484ef","attributeTranslation":"Efficacité: évaluation fonctionnelle musculaire:\n- Echelle North Star Assessment for neuromuscular Disorders (NSAD)\n- Performance of Upper Limb (PUL version 2.0)","language":34,"languageDescription":"French (France)"}]},{"id":849001,"number":2,"endPoint":"Efficacy: timed Function Tests: 10-meter walk test (10MWT); 100-Meter Walk Test (100MWT); Time to Rise From Floor (RFF); 4-Stair climb test","isPrimary":false,"endPointTranslations":[{"id":8781331,"uuid":"4a0408e0-dfb6-4456-8745-d852c9748b49","attributeTranslation":"Efficacité: Tests chronométrés de la fonction musculaire: \n- Test de marche de 10 mètres : 10-Meter Walk test (10MWT)\n- Test de marche de 100 mètres : 100-Meter Walk test (100MWT)\n- Temps pour se relever depuis le sol : Time to Rise From Floor (RFF)\n- Test des 4 marches : 4-Stair Climb test (4SC)","language":34,"languageDescription":"French (France)"}]},{"id":849002,"number":3,"endPoint":"Efficacy: muscle Strength Tests: Myotools and Hand Held Dynamometry (HHD)","isPrimary":false,"endPointTranslations":[{"id":8781332,"uuid":"13efc224-564e-4f82-b4c5-b0bbedd5e970","attributeTranslation":"Efficacité: tests de la force musculaire:\n- Myotools : Myo-grip, Myo-pinch\n- Hand Held Dynamometry (HHD) en utilisant le MicroFET2","language":34,"languageDescription":"French (France)"}]},{"id":849003,"number":4,"endPoint":"Efficacy: Imaging Assessments: Muscle Nuclear Magnetic Resonance Imaging (NMRI) and spectroscopy: quantitative NMRI (including fat-water separation, based MRI and NMRS) in the lower limbs","isPrimary":false,"endPointTranslations":[{"id":8781333,"uuid":"830ee6f6-7d69-4cc6-9e01-9e15d2c9a455","attributeTranslation":"Efficacité: imagerie:\n- IRM du muscle avec spectroscopie : IRM quantitative (y compris séparation graisse/eau) des membres inférieurs","language":34,"languageDescription":"French (France)"}]},{"id":849004,"number":5,"endPoint":"Efficacy: Respiratory assessments: Pulmonary function tests, including forced vital capacity (FVC), minimal inspiratory/expiratory pressure (MIP/MEP), sniff nasal inspiratory pressure (SNIP) test","isPrimary":false,"endPointTranslations":[{"id":8781334,"uuid":"7e475085-b2dd-4f7f-a9e7-a71adc39e272","attributeTranslation":"Efficacité: évaluation de la fonction respiratoire:\nTests pulmonaires fonctionnels, y compris capacité vitale forcée (FVC), pression minimale inspiratoire et expiratoire (MIP/MEP), sniff nasal inspiratory pressure (SNIP) test","language":34,"languageDescription":"French (France)"}]},{"id":849005,"number":6,"endPoint":"Efficacy: Respiratory assessments: Respiratory questionnaire","isPrimary":false,"endPointTranslations":[{"id":8781335,"uuid":"6f904057-81db-4fb4-b6a7-6f50776dfc78","attributeTranslation":"Efficacité: évaluation de la fonction respiratoire:\nQuestionnaire respiratoire","language":34,"languageDescription":"French (France)"}]},{"id":849006,"number":7,"endPoint":"Efficacy: Muscle Biopsy: Histological assessment, including centronucleation index and fibrosis assessment","isPrimary":false,"endPointTranslations":[{"id":8781336,"uuid":"1a499c3f-2c75-49a5-8e10-056f709d912f","attributeTranslation":"Efficacité: biopsie musculaire\nEvaluation histologique, y compris index de centronucleation index et évaluation de la fibrose","language":34,"languageDescription":"French (France)"}]},{"id":849007,"number":8,"endPoint":"Efficacy: Muscle Biopsy: VCN: quantification of vector copy number per diploid cell","isPrimary":false,"endPointTranslations":[{"id":8781337,"uuid":"ea0a5031-1cc9-49d3-954b-d1137ac51ec8","attributeTranslation":"Efficacité: biopsie musculaire\nVCN : quantification du nombre de copies de vecteur par cellule","language":34,"languageDescription":"French (France)"}]},{"id":849008,"number":9,"endPoint":"Efficacy: Muscle Biopsy: SGCG transgene expression (at protein and mRNA levels)","isPrimary":false,"endPointTranslations":[{"id":8781338,"uuid":"08068470-1d9e-4d9d-8037-ccbd0b047587","attributeTranslation":"Efficacité: biopsie musculaire\nExpression du transgène SGCG (au niveau protéique et ARNm)","language":34,"languageDescription":"French (France)"}]},{"id":849009,"number":10,"endPoint":"Efficacy: Muscle Biopsy: Quantification of human sarcolemmal SGCG-positive fibers by immunohistochemistry","isPrimary":false,"endPointTranslations":[{"id":8781339,"uuid":"4080c196-a9bf-4fc8-a70c-8e1e5379b989","attributeTranslation":"Efficacité: biopsie musculaire\nQuantification des fibres positives à la SGCG par immunohistochimie","language":34,"languageDescription":"French (France)"}]},{"id":849010,"number":11,"endPoint":"Efficacy: Muscle Biopsy: Quantification of human alpha-sarcoglycan positive fibers by immunohistochemistry","isPrimary":false,"endPointTranslations":[{"id":8781340,"uuid":"1bb5819d-ea45-4ccd-b068-e9b7c153ce37","attributeTranslation":"Efficacité: biopsie musculaire\nQuantification des fibres positives à l’alpha-sarcoglycan par immunohistochimie","language":34,"languageDescription":"French (France)"}]},{"id":849011,"number":12,"endPoint":"Efficacy: Muscle Biopsy: Exploratory biomarkers, e.g., TMEM8 for regeneration, FN1 for fibrosis, and CD11b for inflammation, microRNA","isPrimary":false,"endPointTranslations":[{"id":8781341,"uuid":"3cf0b957-1fc5-4a62-b099-2ff65605b981","attributeTranslation":"Efficacité: biopsie musculaire:\nBiomarqueurs exploratoires, e.g., TMEM8 pour régénération, FN1 pour fibrose, et CD11b pour inflammation, microRNA","language":34,"languageDescription":"French (France)"}]},{"id":849012,"number":13,"endPoint":"Efficacy: Patient reported outcome and QoL: Fatigue Visual Analog Scale (VAS)","isPrimary":false,"endPointTranslations":[{"id":8781342,"uuid":"598e39d5-75ce-41b1-a8c2-dc61c8018e73","attributeTranslation":"Efficacité: évaluation de la qualité de vie: Echelle de Fatigue","language":34,"languageDescription":"French (France)"}]},{"id":849013,"number":14,"endPoint":"Efficacy: Patient reported outcome and QoL: EQ-5D-Y and EQ-5D-Y proxy 1 questionnaires (based on patient age)","isPrimary":false,"endPointTranslations":[{"id":8781343,"uuid":"b0e9e28e-a50b-4596-aa56-2fc4733f88a3","attributeTranslation":"Efficacité: évaluation de la qualité de vie: EQ-5D-Y et EQ-5D-Y proxy 1 questionnaires (en fonction de l’âge)","language":34,"languageDescription":"French (France)"}]},{"id":849014,"number":15,"endPoint":"Efficacy: Patient reported outcome and QoL: Daily activity living (ACTIVLIM neuromuscular scale)","isPrimary":false,"endPointTranslations":[{"id":8781344,"uuid":"2ca06f15-dd77-4c96-8e0e-081a833add07","attributeTranslation":"Efficacité: évaluation de la qualité de vie: \nEchelle de limitation des activités quotidiennes (ACTIVLIM neuromuscular scale)","language":34,"languageDescription":"French (France)"}]},{"id":849015,"number":16,"endPoint":"Efficacy: Patient reported outcome and QoL: Change in video outcomes capturing disease hallmarks","isPrimary":false,"endPointTranslations":[{"id":8781345,"uuid":"c920c9be-5ff8-4d8c-abc7-d8604c72cc91","attributeTranslation":"Efficacité: évaluation de la qualité de vie: \nChangement dans les résultats vidéo capturant les caractéristiques de la maladie","language":34,"languageDescription":"French (France)"}]},{"id":849016,"number":17,"endPoint":"Efficacy: Biomarkers: Creatine kinase (CK), myomesin-3, circulating microRNA","isPrimary":false,"endPointTranslations":[{"id":8781346,"uuid":"43d12fa3-cf68-4189-bf5b-ffcf8c456161","attributeTranslation":"Efficacité: biomarqueurs\nCreatine kinase (CK), myomesin-3, circulating microRNA","language":34,"languageDescription":"French (France)"}]},{"id":849017,"number":18,"endPoint":"Efficacy: Biomarkers: Blood and urine biobanking","isPrimary":false,"endPointTranslations":[{"id":8781347,"uuid":"e4f8961b-6af5-4e13-9a54-071874e85d26","attributeTranslation":"Efficacité: biomarqueurs:\nBiobanque sang et urine","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedEndDate":"2030-01-01","estimatedRecruitmentStartDate":"2024-01-01"},"sourceOfMonetarySupport":[{"id":79031,"organisationName":"ATAMYO THERAPEUTICS"}],"populationOfTrialSubjects":{"ageRanges":[{"id":298492,"ageRangeCategoryCode":"2","ageRangeCategory":"2"}],"ageRangeSecondaryIds":[{"id":298493,"ageRangeCategoryCode":"2","ctAgeRangeCode":"5","ageRangeCategory":"2","ctAgeRange":"5"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":158063,"businessKey":"1","title":"Part 1: dose escalation phase","description":"The dose escalation phase will enroll ambulant patients with LGMDR5. \nTwo dose cohorts (C1) and (C2) will be enrolled sequentially and enrolment will be staggered with at least 4-week interval between 2 patient treatments. \nCohort C1 of 3 patients will receive 1.0E+14 vg/Kg\nCohort C2 of 3 patients will receive 3.0E+14 vg/Kg\nThe duration of Part 1 is 28 weeks.\nEnrolment of three (3) patients in the 2nd higher dose cohort C2 will be initiated following review of the one-month safety data post-administration in cohort C1 by an independent Data Safety Monitoring Board (DSMB).","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"Three patients will receive 1.0E+14 vg/Kg","title":"Part 1 Cohort 1","id":89130},{"description":"Three patients will receive 3.0E+14 vg/Kg following review of the one-month safety data post-administration in cohort C1 by an independent DSMB.","title":"Part 1 Cohort 2","id":89131}],"allocationMethod":"2"},{"id":158064,"businessKey":"2","title":"Part 2: Long-Term Follow-up for additional 4.5 years","description":"All subjects will be followed up for an additional 4.5 years after completion of Part 1","blindingMethodCode":"3","blindedRoles":[],"armDetails":[{"description":"All subjects having received the treatment will be followed up for an additional 4.5 years after completion of Part 1","title":"Part 2 Long-term Follow-up","id":89132}],"allocationMethod":"2"}]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","therapeuticAreas":[{"code":"5","name":"Diseases [C] - Musculoskeletal Diseases [C05]"}],"medicalConditions":[{"id":112654,"medicalCondition":"limb-girdle muscular dystrophy type R5 (previously named LGMD2C)","isConditionRareDisease":true}],"sponsors":[{"id":122320,"primary":true,"publicContacts":[{"id":360966,"type":"Public","functionalName":"Chief Medical officer","functionalEmailAddress":"contact@atamyo.com","telephone":"+33638682337","organisation":{"id":78268,"type":"Pharmaceutical company","typeCode":"10","name":"Atamyo Therapeutics","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100035122","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":360967,"type":"Scientific","functionalName":"Chief Medical officer","functionalEmailAddress":"contact@atamyo.com","telephone":"+33638682337","organisation":{"id":78268,"type":"Pharmaceutical company","typeCode":"10","name":"Atamyo Therapeutics","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100035122","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":543173,"organisationAddress":{"id":84159,"organisation":{"id":86772,"type":"Pharmaceutical company","typeCode":"10","name":"RLM Consulting","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100009104","organisationLocationStatus":"Active"},"address":{"addressId":88196,"oneLine":"Chemin Du Cyclotron 6","addressLine1":"Chemin Du Cyclotron 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Ottignies-Louvain-La-Neuve","postcode":"1348","country":2002,"countryName":"Belgium"},"phone":"003210390015","email":"regulatory@rlmconsulting.be","isBusinessKeyValidated":true,"businessKey":"LOC-100013588"},"sponsorDuties":[{"id":845446,"code":"12"},{"id":845447,"code":"15","value":"CT Admin in CTIS"}],"phoneNumber":"003210390015","email":"regulatory@rlmconsulting.be"},{"id":543172,"organisationAddress":{"id":84405,"organisation":{"id":87022,"type":"Pharmaceutical company","typeCode":"10","name":"Clinigen Clinical Supplies Management","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100034422","organisationLocationStatus":"Active"},"address":{"addressId":88452,"oneLine":"Watson And Crick Hill, Rue Granbonpre 11","addressLine1":"Watson And Crick Hill","addressLine2":"Rue Granbonpre 11","addressLine3":"","addressLine4":"","city":"Mont-Saint-Guibert","postcode":"1435","country":2002,"countryName":"Belgium"},"phone":"003210237444","email":"contact@clinigencsm.com","isBusinessKeyValidated":true,"businessKey":"LOC-100054547"},"sponsorDuties":[{"id":845445,"code":"14"}],"phoneNumber":"003210237444","email":"contact@clinigencsm.com"}],"organisation":{"id":78268,"type":"Pharmaceutical company","typeCode":"10","name":"Atamyo Therapeutics","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100035122","organisationLocationStatus":"Active"},"addresses":[{"id":75759,"organisation":{"id":78268,"type":"Pharmaceutical company","typeCode":"10","name":"Atamyo Therapeutics","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100035122","organisationLocationStatus":"Active"},"address":{"addressId":79425,"oneLine":"1 B Rue De L Internationale","addressLine1":"1 B Rue De L Internationale","addressLine2":"","addressLine3":"","addressLine4":"","city":"Evry","postcode":"91000","country":2012,"countryName":"France"},"phone":"638682337","email":"s.olivier&#64;atamyo.com","isBusinessKeyValidated":true,"businessKey":"LOC-100055684"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase 1-2: safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy","partOneTherapeuticAreas":[{"id":1019298,"therapeuticArea":{"code":"5","name":"Diseases [C] - Musculoskeletal Diseases [C05]"}}],"productRoleGroupInfos":[{"id":338014,"comments":"Rapamune 1 mg/mL oral solution","miaNumber":"1573 IMP","productRoleCode":"4","productRoleName":"Auxiliary","products":[{"id":450765,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9865104","productPharmForm":"ORAL SOLUTION","euMpNumber":"PRD3342092","marketingAuthNumber":"EU/1/01/171/001","prodAuthStatus":2,"prodName":"Rapamune 1 mg/mL oral solution","pharmForm":"ORAL SOLUTION","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/000273","nameOrg":"PFIZER EUROPE MA EEIG","productSubstances":[{"productPk":"9865104","substancePk":"233258","nameOrg":"PFIZER EUROPE MA EEIG","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG","synonyms":["SEL-110.36","RAPAMYCIN","NPG-12G","(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone"]}],"atcCode":"L04AA10","atcName":"SIROLIMUS","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"immunosuppressant","evCode":"PRD3342092","sponsorProductCodeEdit":"Sirolimus","miaNumber":"1573 IMP","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"Rapamune 1 mg/mL oral solution","jsonActiveSubstanceNames":"sirolimus","pharmaceuticalFormDisplay":"ORAL SOLUTION"}]},{"id":338013,"comments":"PREDNISOLONE","miaNumber":"1573 IMP","productRoleCode":"4","productRoleName":"Auxiliary","products":[{"id":450764,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00082MIG","euMpNumber":"SCP15687495","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"ABIRATERONE ACETATE","euSubstNumber":"SUB31647","productSubstances":[{"substancePk":"430598","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"ABIRATERONE ACETATE","substanceEvCode":"SUB31647","synonyms":[]}],"atcCode":"H02AB06","atcName":"PREDNISOLONE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"glucocorticoid","sponsorProductCodeEdit":"Prednisolone","miaNumber":"1573 IMP","scientificProductEvCode":"SCP15687495","scientificProductPharmEvCode":"PHF00082MIG","devices":[],"characteristics":["11"],"routes":["ORAL"],"allSubstancesChemicals":true,"productName":"PREDNISOLONE","jsonActiveSubstanceNames":"abiraterone acetate","pharmaceuticalFormDisplay":"PHF00082MIG"}]},{"id":338016,"comments":"rAAV8-hSGCG","productRoleCode":"1","productRoleName":"Test","products":[{"id":450767,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10196403","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD10196403","prodAuthStatus":1,"prodName":"rAAV8-hSGCG","pharmForm":"SOLUTION FOR INFUSION","sponsorProductCode":"ATA-200","activeSubstanceName":"ADENO-ASSOCIATED VIRUS SEROTYPE 8 EXPRESSING THE HUMAN GAMMA-SARCOGLYCAN GENE","euSubstNumber":"SUB254592","nameOrg":"ATAMYO THERAPEUTICS","productSubstances":[{"productPk":"10196403","substancePk":"258374","nameOrg":"ATAMYO THERAPEUTICS","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"ADENO-ASSOCIATED VIRUS SEROTYPE 8 EXPRESSING THE HUMAN GAMMA-SARCOGLYCAN GENE","substanceEvCode":"SUB254592","synonyms":["ATA-200","Adeno-associated virus serotype 8 containing the SGCG gene"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EMA/OD/0000078678","otherMedicinalProduct":"GTMP: genetically modified recombinant viral: vector serotype 8 of the adeno-associated virus (AAV)","evCode":"PRD10196403","sponsorProductCodeEdit":"ATA-200","therapies":[{"id":5639,"advancedTherapyType":"3","geneOfInterest":"human Sarcoglycan Gamma","description":"ATA-200 is a genetically modified recombinant (r) viral vector composed of the viral capsid of the serotype 8 of the adeno-associated virus (AAV) and the complementary DNA (cDNA) sequence (hSGCG) encoding for the human gamma-sarcoglycan under the transcriptional control of the human muscle creatine kinase promoter (tMCK)","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"rAAV8-hSGCG","jsonActiveSubstanceNames":"adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]},{"id":338015,"comments":"METHYLPREDNISOLONE","miaNumber":"1573 IMP","productRoleCode":"4","productRoleName":"Auxiliary","products":[{"id":450766,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00243MIG","euMpNumber":"SCP65085035","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"LIDOCAINE HYDROCHLORIDE MONOHYDRATE, METHYLPREDNISOLONE ACETATE","euSubstNumber":"SUB02922MIG, SUB03255MIG","productSubstances":[{"substancePk":"431385","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"LIDOCAINE HYDROCHLORIDE MONOHYDRATE","substanceEvCode":"SUB02922MIG","synonyms":[]},{"substancePk":"423458","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"METHYLPREDNISOLONE ACETATE","substanceEvCode":"SUB03255MIG","synonyms":[]}],"atcCode":"H02AB04","atcName":"METHYLPREDNISOLONE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"productChangedRelationMA":false,"otherMedicinalProduct":"Glucocorticoids","sponsorProductCodeEdit":"Methylprednisolone","miaNumber":"1573 IMP","scientificProductEvCode":"SCP65085035","scientificProductPharmEvCode":"PHF00243MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS BOLUS USE"],"allSubstancesChemicals":true,"productName":"METHYLPREDNISOLONE","jsonActiveSubstanceNames":"lidocaine hydrochloride monohydrate, methylprednisolone acetate","pharmaceuticalFormDisplay":"PHF00243MIG"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":33427,"mscId":13144,"mscInfo":{"id":13144,"clinicalTrialId":6806,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2023-08-02","toDate":"2023-08-02","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2024-02-20","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":19401,"mscId":13144,"trialStatus":"Under evaluation","trialStatusDate":"2023-12-20T13:20:46.881"},{"id":24274,"mscId":13144,"trialStatus":"Authorised","trialStatusDate":"2024-02-20T16:27:51.788"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2024-02-19","decision":"authorized","decisionDate":"2024-02-20"},"decisionDate":"2024-02-20","recruitmentSubjectCount":3,"trialSites":[{"id":357684,"organisationAddressInfo":{"id":288576,"organisation":{"id":292595,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006307","organisationLocationStatus":"Active"},"address":{"addressId":307821,"oneLine":"Via Francesco Sforza 28","addressLine1":"Via Francesco Sforza 28","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20122","country":2018,"countryName":"Italy"},"phone":"0255033802","email":"giacomo.comi@policlinico.mi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100006307"},"personInfo":{"id":410769,"firstName":"Giacomo","lastName":"Comi","telephone":"0255033802","email":"giacomo.comi@policlinico.mi.it","title":"2"},"departmentName":"Neurology"}],"applicationStatusCode":"Authorised"},{"id":259664,"mscId":13143,"mscInfo":{"id":13143,"clinicalTrialId":6806,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-02-23","toDate":"2024-02-23","isProposedRms":true,"expressDecision":"willing","countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-03-11","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":true,"clinicalTrialStatusHistory":[{"id":19400,"mscId":13143,"trialStatus":"Under evaluation","trialStatusDate":"2023-12-20T13:20:46.868"},{"id":26475,"mscId":13143,"trialStatus":"Authorised","trialStatusDate":"2024-03-11T18:58:57.79"}],"applicationTypeMsc":"1","mscName":"France","recruitmentRestartDate":"2028-03-11","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-12-09","decision":"authorized","decisionDate":"2024-03-11"},"decisionDate":"2024-03-11","recruitmentSubjectCount":2,"trialSites":[{"id":1773960,"organisationAddressInfo":{"id":287634,"organisation":{"id":291650,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Association Institut De Myologie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100046467","organisationLocationStatus":"Active"},"address":{"addressId":306809,"oneLine":"Porte 20 2eme Etage, 26 Avenue Du Docteur Arnold Netter","addressLine1":"Porte 20 2eme Etage","addressLine2":"26 Avenue Du Docteur Arnold Netter","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75012","country":2012,"countryName":"France"},"phone":"0171738042","email":"m.colella@institut-myologie.org","isBusinessKeyValidated":true,"businessKey":"ORG-100046467"},"personInfo":{"id":1971892,"firstName":"Marina","lastName":"Colella","telephone":"0171738042","email":"m.colella@institut-myologie.org","title":"1"},"departmentName":"Neurology"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":9223,"type":"INITIAL","status":"Authorised","ctNumber":"2023-506440-16-00","trialStatus":"Authorised","submissionDate":"2023-08-08","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2023-12-08"},"partIIInfo":[{"id":74711,"mscId":13143,"mscInfo":{"id":13143,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-03-11","decision":"authorized","decisionDate":"2024-03-11","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-03-11"},"applicationStatusCode":"Authorised"},{"id":33427,"mscId":13144,"mscInfo":{"id":13144,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2024-02-19","decision":"authorized","decisionDate":"2024-02-20","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-02-20"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-02-20","ctMSCsByApplication":[{"id":13143,"mscName":"France","reportingStatusCode":"Authorised"},{"id":13144,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":15417,"applicationId":9223,"mscId":13143,"mscName":"France","decisionDate":"2024-03-11T18:58:58.072","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":74711,"part1Id":22288,"applicationType":"INITIAL","isRMS":true},{"id":13759,"applicationId":9223,"mscId":13144,"mscName":"Italy","decisionDate":"2024-02-20T16:27:52.082","decision":"authorized","assessmentOutcome":"no_conclusion","eventType":"decision","part2Id":33427,"part1Id":22288,"applicationType":"INITIAL","isRMS":false}]},{"id":70715,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506440-16-00","trialStatus":"Authorised","submissionDate":"2025-11-21","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":259664,"mscId":13143,"mscInfo":{"id":13143,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-12-09","decision":"authorized","decisionDate":"2024-03-11","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-03-11"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-12-10","ctMSCsByApplication":[{"id":13143,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":101614,"applicationId":70715,"mscId":13143,"mscName":"France","decisionDate":"2025-12-10T08:54:51.776","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":259664,"part1Id":108754,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":13143,"firstDecisionDate":"2024-03-11T18:58:58.072","lastDecisionDate":"2025-12-10T08:54:51.776","mscPublicStatusCode":2},{"mscName":"Italy","mscId":13144,"firstDecisionDate":"2024-02-20T16:27:52.082","lastDecisionDate":"2024-02-20T16:27:52.082","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":13143,"mscName":"France","events":[]},{"mscId":13144,"mscName":"Italy","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"K1_ATA-003-GSAR_FRA_Recruitment arrangements_fre_FP","uuid":"f1199158-41cb-461e-b59f-001d0bcc04dd","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"NA","systemVersion":"1"},{"title":"K2_ATA-003-GSAR_FRA_Study flyer_fre_FP","uuid":"bedd24ab-eed1-4ec2-8f3c-15357f447b0a","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ATA-003-GSAR_FRA_ICF_Parents_fre_FP","uuid":"063fb77b-f05e-4315-b859-74a6e5ad2c93","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1-1","systemVersion":"1"},{"title":"L1_ATA-003-GSAR_FRA_ICF_Prescreening_Parents_fre_FP","uuid":"a8270a9a-549c-4aaa-a07e-d6222f40ee59","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1-1","systemVersion":"1"},{"title":"L1_ATA-003-GSAR_FRA_Assent_Minors_fre_FP","uuid":"3ee534b0-e270-48cf-8f98-dcdcd141088d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1-1","systemVersion":"1"},{"title":"L1_ATA-003-GSAR_FRA_Assent_PreScreening_Minors_fre_FP","uuid":"ff90a035-a52d-41c6-955c-149c39dd44c7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1-1","systemVersion":"1"},{"title":"L1_ATA-003-GSAR_FRA_ICF Biobanking_Parents_FP","uuid":"6d9adf7f-f7bd-493f-9078-6a02f43ab360","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":259664,"manualVersion":"1-1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}